权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk

胃肠道干细胞平面培养用于筛选药物不良事件风险

基本信息

批准号：
10482465
负责人：
Christopher Eldridge Sims
金额：
$ 25.66万
依托单位：
ALTIS BIOSYSTEMS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-01 至 2023-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10482465
关键词：
3-Dimensional Address Adherent Culture Adverse event Animal Model Animals Apical Area Ascending colon Benchmarking Biological Assay Biomimetics Cell Culture Techniques Cell Proliferation Cell Survival Cell physiology Cells Cellular Structures Cessation of life Characteristics Clinical Clinical Trials Collaborations Collection Colon Data Descending colon Detection Development Diarrhea Disease Dose Dose-Limiting Drug Evaluation Drug Screening Duodenum Electrical Resistance Engineering Epithelial Exposure to Gastrointestinal Physiology Gastrointestinal tract structure Goals Human In Vitro Industry Inflammation Intestines Laboratories Lead Literature Manufacturer Name Measurement Measures Membrane Microinjections Modality Modeling Monitor Oncology Organ Donor Organ Transplantation Organoids Performance Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phase Phenotype Physiology Population Property Rattus Reproducibility Risk S phase Sampling Screening procedure Side Small Intestines Source Stains Surface Technology Testing Therapeutic Therapeutic Agents Therapeutic Effect Tissue Donors Tissues Toxic effect Transformed Cell Line Transverse colon Tumor Cell Line Tumor-Derived Ulcer Variant adverse event risk base biobank cell type cost effective drug testing gastrointestinal gastrointestinal epithelium gastrointestinal system high risk ileum in vitro Assay in vitro Model in vivo indexing intestinal epithelium jejunum manufacturing process monolayer novel novel therapeutics phase III trial preclinical safety preclinical study prevent programs regenerative cell repaired research clinical testing scaffold screening side effect stem stem cell differentiation stem cell population stem cell proliferation stem cells stemness success therapeutic candidate transcriptomics

项目摘要

Project Summary GI side effects, such as ulcers and diarrhea, represent the most common source of adverse events for pharmaceuticals. GI stem cells are responsible for repairing and replenishing GI epithelium, and pharmaceutical inhibition of these functions likely contribute to adverse event risk. Currently there are no high-throughput and cost-effective means of screening candidate therapeutics for effects on GI stem cells. Animal models are fraught with confounds (e.g., rats generally do not exhibit diarrhea until death is imminent) and current in vitro models like the Caco-2 tumor cell line do not include a normal stem cell population. While 3D-organoid cultures have a stem cell component, access to the apical aspect of the monolayer for compound exposure is not possible without low-throughput microinjection. Altis Biosystems, Inc. has developed a proprietary culture platform, RepliGut® Planar, enabling primary human GI cells to form an epithelium for drug screening. In preliminary efforts, we initiated development of a GI stem cell-specific platform called RepliGut® StemScreen to address the unmet need for high-throughput, cost-effective GI stem cell screening, including a range of assays to measure properties that might lead to adverse events. These include assays for proliferation using S-phase staining and assessing downstream differentiation and ability to establish barrier function via non-destructive transepithelial electric resistance (TEER) analysis. A panel of pharmaceutical agents associated with clinically adverse GI side effects, tested in a classic EdU assay using StemScreen planar cultures, demonstrated dose-dependent inhibition of stem cell proliferation and prevented stem cell differentiation into a mature epithelium with barrier function. During Phase I we will: 1) characterize monolayer proliferation properties of donor cells in the Altis biobank(initially transverse colon stem cells will be evaluated, with other regions tested in Phase II) from three donors and 2) test a selection of therapeutic agents with known GI adverse event risks for effects on stem cell proliferation, impacting differentiation and the formation of a functional epithelial barrier (indexed as TEER). Demonstrating that the StemScreen platform provides an in vitro screening tool capable of predicting a drug’s risk for GI adverse events in Phase I will enable deeper characterization of stemness, stem cells from other GI regions (e.g., ascending and descending colon; small intestine regions including jejunum, etc.), and stem cell phenotypes. In Phase 2, we plan externally validate the platform in collaboration with leading industry laboratories prior to commercial launch.

项目总结